Mi Guo-Lin, Zhao Lei, Qiao Dong-Dong, Kang Wen-Qing, Tang Mao-Qin, Xu Jin-Ke
Shandong University School of Medicine, Jinan, 250012, Shandong, China.
Antonie Van Leeuwenhoek. 2015 Jun;107(6):1547-53. doi: 10.1007/s10482-015-0448-9. Epub 2015 Apr 16.
Infant colic, excessive crying of unknown cause, is a major burden to families and effects about 10-30 % of infants. Despite decades of research, the exact cause and treatment of infant colic has remained elusive. The use of Lactobacillus reuteri (DSM 17938) in infant colic is somewhat controversial and hence, we designed this study to evaluate its efficacy in infantile colic. We recruited predominantly or exclusively breastfed infants, aged less than 4 months in a placebo controlled observational randomized study. Participants' were assigned to receive L. reuteri at a dose 10(8) colony forming units (n = 21) and placebo (n = 21). Placebo was an identical formulation without live micro-organisms. Treatment was given to subjects for 21 days and they were followed for 4 weeks. Treatment success (primary outcome), daily reduction in crying time, parent satisfaction and reduction in maternal depression (secondary outcomes) were assessed at the end of study period. Treatment success was observed in all infants (100 %) of the probiotic group while it was seen in 15.7 % of the placebo group. Mean daily crying time was more significantly reduced to 32.1 ± 8.3 min/day (P < 0.01) from 200.9 ± 6.3 min/day in the probiotic group as compared to the placebo group (120.6 ± 20.0 min/day). Moreover, throughout the study period, parent's satisfaction and improvement in maternal depression (Edinburgh postnatal depression scale) was also significantly higher in the probiotic group. In our study population, reduction in crying time was significant (P < 0.01) even during first week of initiation of therapy. We conclude that L. reuteri (DSM 17938) reduces daily crying time and maternal depression during infantile colic. We suggest L. reuteri may be a safe and efficacious option for reducing infant colic.
婴儿腹绞痛是指不明原因的过度哭闹，这给家庭带来了沉重负担，约10%至30%的婴儿受其影响。尽管经过数十年研究，婴儿腹绞痛的确切病因和治疗方法仍不明确。罗伊氏乳杆菌（DSM 17938）用于治疗婴儿腹绞痛存在一定争议，因此，我们设计了本研究来评估其对婴儿腹绞痛的疗效。在一项安慰剂对照观察性随机研究中，我们招募了主要或完全母乳喂养、年龄小于4个月的婴儿。参与者被分配接受剂量为10⁸菌落形成单位的罗伊氏乳杆菌（n = 21）和安慰剂（n = 21）。安慰剂是不含活微生物的相同制剂。对受试者进行21天治疗，并随访4周。在研究期结束时评估治疗成功率（主要结局）、每日哭闹时间减少情况、家长满意度和母亲抑郁程度降低情况（次要结局）。益生菌组所有婴儿（100%）均观察到治疗成功，而安慰剂组为15.7%。与安慰剂组（120.6±20.0分钟/天）相比，益生菌组平均每日哭闹时间从200.9±6.3分钟/天显著减少至32.1±8.3分钟/天（P < 0.01）。此外，在整个研究期间，益生菌组家长的满意度以及母亲抑郁程度的改善（爱丁堡产后抑郁量表）也显著更高。在我们的研究人群中，即使在治疗开始的第一周，哭闹时间的减少也很显著（P < 0.01）。我们得出结论，罗伊氏乳杆菌（DSM 17938）可减少婴儿腹绞痛期间的每日哭闹时间和母亲抑郁程度。我们建议罗伊氏乳杆菌可能是减轻婴儿腹绞痛的一种安全有效的选择。
